Last reviewed · How we verify
HES 10%
HES 10% is a hydroxyethyl starch colloid that expands intravascular volume by increasing plasma oncotic pressure to maintain fluid balance.
HES 10% is a hydroxyethyl starch colloid that expands intravascular volume by increasing plasma oncotic pressure to maintain fluid balance. Used for Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma, Perioperative fluid management in patients undergoing major surgery.
At a glance
| Generic name | HES 10% |
|---|---|
| Sponsor | B. Braun Melsungen AG |
| Drug class | Synthetic colloid plasma volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
HES 10% is a synthetic colloid composed of hydroxyethyl starch dissolved in crystalloid solution. It functions as a volume expander by increasing the oncotic pressure of blood plasma, thereby drawing and retaining fluid in the intravascular space. This mechanism helps restore circulating blood volume in patients with acute blood loss or hypovolemia.
Approved indications
- Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma
- Perioperative fluid management in patients undergoing major surgery
Common side effects
- Increased bleeding risk
- Acute kidney injury
- Hyperchloremic acidosis
- Coagulopathy
- Anaphylactic reactions
Key clinical trials
- Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome (PHASE2)
- A Dose-Image Optimization Trial Evaluating Mannitol and Voluven as Adjuncts for Indocyanine Green (PHASE1, PHASE2)
- Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery (PHASE4)
- Stroke Volume Variation and Plethysmography Variability Index as Goal Directed Fluid Therapy in Major Oncosurgeries (NA)
- Effect of Hypopressive Exercises on Postpartum Backache and Functional Disability (NA)
- Comparison of Different HES Coload Volumes on the 90% ED of Norepinephrine (NA)
- Spectral Analysis of Central Venous Pressure Waveform
- Comparison of Hydroxyethyl Starch and Crystalloid Coload Combined With Norepinephrine Infusion for Hypotension (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HES 10% CI brief — competitive landscape report
- HES 10% updates RSS · CI watch RSS
- B. Braun Melsungen AG portfolio CI